Covered recipient · General Payments record
LINDA J BANTA
Allopathic & Osteopathic Physicians Dermatology
General Payments · PY2018–2024
$39,340.78
- Reported across 430 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $321.79 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $108.98 | 5 |
| Amgen Inc. | $49.16 | 2 |
| E.R. Squibb & Sons, L.L.C. | $42.26 | 2 |
| Lilly USA, LLC | $40.45 | 2 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $26.48 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $23.81 | 1 |
| REVANCE THERAPEUTICS, INC. | $16.52 | 1 |
| Janssen Biotech, Inc. | $14.13 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $20.06 | 03/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103276475 | CMS |
| ABBVIE INC. | $24.67 | 04/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103276477 | CMS |
| ABBVIE INC. | $21.94 | 05/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103276479 | CMS |
| ABBVIE INC. | $27.17 | 09/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103276481 | CMS |
| ABBVIE INC. | $15.14 | 09/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103276483 | CMS |
| Amgen Inc. | $23.50 | 01/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117197371 | CMS |
| Amgen Inc. | $25.66 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117197373 | CMS |
| E.R. Squibb & Sons, L.L.C. | $21.72 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101520462 | CMS |
| E.R. Squibb & Sons, L.L.C. | $20.54 | 04/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101520484 | CMS |
| Janssen Biotech, Inc. | $14.13 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078765507 | CMS |
| Lilly USA, LLC | $20.95 | 01/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135089845 | CMS |
| Lilly USA, LLC | $19.50 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135154270 | CMS |
| Novartis Pharmaceuticals Corporation | $23.81 | 02/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086677499 | CMS |
| REVANCE THERAPEUTICS, INC. | $16.52 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147912290 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $26.48 | 09/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1152174575 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.